975 related articles for article (PubMed ID: 30092234)
21. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.
Guyot E; Sutton A; Rufat P; Laguillier C; Mansouri A; Moreau R; Ganne-Carrié N; Beaugrand M; Charnaux N; Trinchet JC; Nahon P
J Hepatol; 2013 Feb; 58(2):312-8. PubMed ID: 23069476
[TBL] [Abstract][Full Text] [Related]
22. Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis.
Rong G; Wang H; Bowlus CL; Wang C; Lu Y; Zeng Z; Qu J; Lou M; Chen Y; An L; Yang Y; Gershwin ME
Clin Rev Allergy Immunol; 2015 Jun; 48(2-3):132-41. PubMed ID: 25762349
[TBL] [Abstract][Full Text] [Related]
23. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C.
Yamauchi M; Nakahara M; Maezawa Y; Satoh S; Nishikawa F; Ohata M; Mizuhara Y; Hirakawa J; Nakajima H; Fujisawa K
Am J Gastroenterol; 1993 Jan; 88(1):39-43. PubMed ID: 7678368
[TBL] [Abstract][Full Text] [Related]
25. Risk of development of hepatocellular carcinoma in patients with NASH-related cirrhosis.
Amarapurkar DN; Dharod M; Gautam S; Patel N
Trop Gastroenterol; 2013; 34(3):159-63. PubMed ID: 24851525
[TBL] [Abstract][Full Text] [Related]
26. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
27. [Alcoholic liver cirrhosis. Screening for hepatocellular carcinoma in liver cirrhosis].
Trinchet JC; Beaugrand M
Presse Med; 2001 Jul 7-13; 30(23):1164-9. PubMed ID: 11505839
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes.
Jones DE; Metcalf JV; Collier JD; Bassendine MF; James OF
Hepatology; 1997 Nov; 26(5):1138-42. PubMed ID: 9362353
[TBL] [Abstract][Full Text] [Related]
29. Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India.
Paul SB; Sreenivas V; Gulati MS; Madan K; Gupta AK; Mukhopadhyay S; Panda SK; Acharya SK
Indian J Gastroenterol; 2007; 26(6):274-8. PubMed ID: 18431010
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma in the setting of alcohol-related liver disease.
Ganne-Carrié N; Nahon P
J Hepatol; 2019 Feb; 70(2):284-293. PubMed ID: 30658729
[TBL] [Abstract][Full Text] [Related]
31. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
[TBL] [Abstract][Full Text] [Related]
32. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.
Chen TH; Chen CJ; Yen MF; Lu SN; Sun CA; Huang GT; Yang PM; Lee HS; Duffy SW
Int J Cancer; 2002 Mar; 98(2):257-61. PubMed ID: 11857416
[TBL] [Abstract][Full Text] [Related]
33. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
34. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
[TBL] [Abstract][Full Text] [Related]
35. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
Trinchet JC; Bourcier V; Chaffaut C; Ait Ahmed M; Allam S; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Buffet C; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Thiefin G; Hillaire S; Di Martino V; Nahon P; Chevret S;
Hepatology; 2015 Sep; 62(3):737-50. PubMed ID: 25678021
[TBL] [Abstract][Full Text] [Related]
36. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
37. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
38. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
[TBL] [Abstract][Full Text] [Related]
39. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients.
Poh Z; Goh BB; Chang PE; Tan CK
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):638-43. PubMed ID: 25831135
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and outcome of hepatocellular carcinoma in alcohol related and cryptogenic cirrhosis: a prospective study.
Siriwardana RC; Niriella MA; Dassanayake AS; Liyanage C; Gunathilaka B; Jayathunge S; de Silva HJ
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):401-5. PubMed ID: 26256085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
